Kristi Rosa

Janakiraman Subramanian, MD, discusses ongoing advances and remaining challenges in the field of lung cancer.

Brandon Weckbaugh, MD, sheds light on emerging biomarkers in non–small cell lung cancer.

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Results from a recent retrospective study indicate that treatment with a gastrointestinal-based adjuvant chemotherapy regimen may be more beneficial than that of a gynecologic-based one in patients with mucinous ovarian cancer.

John Mendelsohn, MD, a 2016 Giants of Cancer Care® in Scientific Advances in recognition of his groundbreaking research that led to the development of cetuximab, died January 7 at his home in Houston, Texas at the age of 82.

John F. Seymour, MBBS, PhD, discusses the clinical implications of the MURANO trial and highlights the feasibility for time-limited therapy and its benefits for patients with chronic lymphocytic leukemia.

Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement with Celgene Corporation under which BMS will acquire Celgene in a cash and stock transaction with an equity value of about $74 billion.

An ongoing randomized phase III study will compare the safety and efficacy of atezolizumab with placebo as adjuvant therapy after definitive local therapy in patients with high-risk, locally advanced squamous cell carcinoma of the head and neck.

Robert J. Cerfolio, MD, discusses how the use of surgery has significantly evolved over the years and how advances made in robotic surgery improve quality of life of those who need to undergo these procedures.

Erdafitinib, an oral pan-FGFR inhibitor, demonstrated encouraging clinical activity and a manageable safety profile in Asian patients with FGFR-aberrant advanced cholangiocarcinoma.

The PD-1 inhibitor cemiplimab in combination with radiotherapy, cyclophosphamide, and GM-CSF did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Ciara O’Sullivan, MB, BCh, discusses the need for treatment de-escalation for patients with HER2-positive breast cancer, as well as the challenges that remain in tailoring treatment.

The FDA has granted an approval to CT-P6, a trastuzumab biosimilar, for the treatment of patients with HER2-overexpressing breast cancer

The monoclonal anti-PD-1 antibody cemiplimab continued to demonstrate considerable antitumor activity and durable responses in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma.

Rachel C. Jankowitz, MD, discusses the range of risk associated with HR-positive, HER2-negative breast cancer and the importance of communicating with patients about associated adverse events.

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Shannon L. Puhalla, MD, discusses some of the advances being made in systemic treatment for patients with brain metastases from breast cancer.

Terry L. Evans, MD, discusses the impact of CDK4/6 inhibitors in the metastatic breast cancer space and challenges that still need to be addressed.

Nisha A. Mohindra, MD, discusses the current treatment landscape, challenges faced in this patient population, and what she believes will be a focus for further research over the next decade.

Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.

Women between the ages of 30 and 39 who have at least 1 of 3 risk factors may benefit from starting their annual mammography screening at age 30.

Ardaman Shergill, MD, discusses the impact of tumor mutational burden, as well as RET and NTRK fusions, in the NSCLC paradigm.

Thomas Hensing, MD, discusses the emergence of immunotherapy in the stage III non–small cell lung cancer armamentarium, and questions that must be answered to build on this initial success.

Adam M. Brufsky, MD, PhD, highlights novel treatment approaches being explored in the triple-negative breast cancer space.

Lawrence E. Feldman, MD, discusses exciting new data surrounding immunotherapy combinations in lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use granted support for approval of apalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.

Pixatimod (PG545) in combination with the PD-1 inhibitor nivolumab (Opdivo) may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.

Vik Gorantla, MD, discusses ongoing developments in the adjuvant setting for patients with HER2-positive breast cancer.

Epoetin alfa-epbx (Retacrit), the biosimilar to epoetin alfa (Procrit/Epogen) has been launched in the United States at a significant discount.